several genes remained unaffected by the extra rapid cell cycles ( fig. S8A ), underlining that several mechanisms regulate mRNA abundance at the MBT (1) .
To understand the physiological importance of the regulation of DNA replication during development, we analyzed the phenotype of embryos overexpressing RecQ4, Treslin, Drf1, and Cut5. Embryos that overexpress these four factors failed to complete gastrulation and blastopore closure at stage 10.5 ( Fig. 4) and underwent cell death by stage 17 (neurula) , showing that titration of these factors is critical for embryogenesis.
If this developmental defect upon overexpression of RecQ4, Treslin, Drf1, and Cut5 is indeed due to increased rates of initiation, we hypothesized that a partial reduction in origin licensing might suppress this phenotype. Injection of embryos with morpholinos against the pre-RC component cdc6 resulted in partial depletion of the Cdc6 protein (Fig. 4, top) , and although this caused a slight delay in blastopore closure, 81% of these morpholino-injected embryos reached the neurula stage (Fig. 4) . However, coinjection of these cdc6 morpholinos together with overexpression of RecQ4, Treslin, Drf1, and Cut5 partially rescued the ability of these embryos to undergo gastrulation, and 38% of embryos survived until stage 17 . This indicates that the developmental deficiency caused by overexpression of RecQ4, Treslin, Drf1, and Cut5 is at least in part due to the resulting increase in replication initiation. The cdc6 morpholinos in combination with the overexpression of limiting initiation factors not only partially rescued the embryonic defect but also restored normal cell cycle elongation and Chk1 activation at the MBT ( fig. S9 ). Together, these experiments demonstrate that the regulation of replication initiation rates is necessary for several of the critical events of the MBT and for normal development in Xenopus laevis.
This study provides a mechanistic basis for the hypothesis put forward 30 years ago that passive depletion of limiting factors by the N/C ratio is the primary mechanism controlling events at the MBT (4). We speculate that the interplay between the limiting replication factors RecQ4, Treslin, Drf1, and Cut5, together with Chk1 activation and CDK inactivation, forms a feedback loop ( fig. S10 ), which in accordance with work in flies (3, 6, 25, 26) 
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Phosphorylated O-mannosyl trisaccharide [N-acetylgalactosamine-b3-N-acetylglucosamine-b4-(phosphate-6-)mannose] is required for dystroglycan to bind laminin-G domain-containing extracellular proteins with high affinity in muscle and brain. However, the enzymes that produce this structure have not been fully elucidated. We found that glycosyltransferase-like domain-containing 2 (GTDC2) is a protein O-linked mannose b 1,4-N-acetylglucosaminyltransferase whose product could be extended by b 1,3-N-acetylgalactosaminyltransferase2 (B3GALNT2) to form the O-mannosyl trisaccharide. Furthermore, we identified SGK196 as an atypical kinase that phosphorylated the 6-position of O-mannose, specifically after the mannose had been modified by both GTDC2 and B3GALNT2. These findings suggest how mutations in GTDC2, B3GALNT2, and SGK196 disrupt dystroglycan receptor function and lead to congenital muscular dystrophy. produces a branch chain that is ultimately extended with repeating disaccharides [-a3-glucuronic acid (GlcA)-b3-xylose (Xyl)-] synthesized by likeacetylglucosaminyltransferase (LARGE), enabling a-DG to bind ECM ligands (3, 4) . Mutations in several known and putative glycosyltransferases cause DG-related disorders. Recently, genetic studies of the DG-related diseases CMD and cobblestone lissencephaly identified several new causative genes, including isoprenoid synthase domain containing (ISPD) (5), transmembrane protein 5 (TMEM5) (6), b1,3-N-acetylglucosaminyltransferase (B3GNT1) (7), glycosyltransferase-like domain containing 2 (GTDC2) (8), b3-N-acetylgalactosaminyltransferase2 (B3GALNT2) (9) , and SGK196 (10). However, the functions of the genes' products remain largely unknown.
O-Mannosyl glycosylation of a-DG is initiated by the endoplasmic reticulum (ER)-resident protein O-mannosyl transferase 1/2 complex (POMT1/2), which adds mannose to Ser/Thr residues (11) . To help to clarify the functions of the recently identified causative proteins, we examined their subcellular localization. GTDC2 was present in the ER (Fig. 1A) , suggesting that it might modify the above-described O-mannose. Thus, we synthesized a peptide corresponding to the mucinlike domain of human a-DG (residues 316 to 329), in which Thr 317 was modified by O-mannose but the remaining Thr/Ser residues were replaced with Ala. The glycopeptide was incubated with c-Myc-tagged GTDC2 (GTDC2-Myc) purified from human embryonic kidney (HEK) 293 cell lysates, as well as various nucleotide sugars. Matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF/MS) analysis suggested that GTDC2-Myc transferred N-acetylhexosamine to the glycopeptide ( fig. S1 ). Repetition of this assay using uridine 5´-diphosphate (UDP)-GlcNAc Reactants of rabbit brain total membrane fraction incubated with ATP and GalNAc-b3-GlcNAc-b4-Man-a-MU at 37°C for 6 hours were separated on a C18 reverse-phase column. S, unreacted acceptor substrate. P, enzymatic product. (Fig. 1B) or UDP-GalNAc ( fig. S2 ) as the donor confirmed that the transfer was specific to GlcNAc and that it did not occur when GTDC2-Myc carrying a mutation found in a CMD patient was used ( fig. S2 ). Next, we prepared a secreted form of GTDC2 (lacking the transmembrane domain; GTDC2dTM) in HEK293 cells ( fig. S3 ) and conducted the transfer assay by using fluorescently labeled mannoside (4-methylumbelliferyl-a-Dmannoside; Man-a-MU) as the acceptor. The product was purified by gel filtration (Fig. 1C C resonances of the product were assigned by using heteronuclear multiple quantum coherence (HMQC) and heteronuclear 2-bond correlation (H2BC) spectra ( fig. S4; Fig. 1 , D and E; table S1). Rotating-frame Overhauser enhancement (ROE) data ( fig. S5) confirmed that GlcNAc has a beta configuration. A BH1/AC4 cross-peak detected by the heteronuclear multiple bond correlation (HMBC) spectrum (Fig. 1F) indicated that the GlcNAc was linked to the 4-position of the mannose. Thus, GTDC2 possesses a protein O-mannose b1,4-N-acetylglucosaminyltransferase activity.
Human B3GALNT2, mutations in which cause WWS (9), has been cloned on the basis of its b3-glycosyltransferase motifs. This enzyme is thought to act as a b1,3-N-acetylgalactosaminyltransferase that uses b-linked GlcNAc as its acceptor in vitro (12) . However, the GalNAc-b3-GlcNAc-b sequence had not been found in mammals when the gene was cloned, leaving the biological importance of this enzyme unclear. a-DG contains an O-mannosyl glycan (GalNAc-b3-GlcNAc-b4-Man), with the mannose phosphorylated at the 6-position (3). The ECM-ligand-binding moiety of a-DG extends from this phosphate residue (3). To test whether B3GALNT2 and GTDC2 act coordinately on O-mannose to synthesize this trisaccharide, we prepared a secreted form of B3GALNT2 (B3GALNT2dTM) ( fig. S6 ) and incubated this protein with UDP-GalNAc and the GlcNAc-b4-Man-O-peptide produced by the GTDC2dTM reaction. MALDI-TOF/MS analysis confirmed that B3GALNT2 could transfer a GalNAc residue to the acceptor ( Fig. 2A) , suggesting that B3GALNT2 and GTDC2 can synthesize GalNAc-b3-GlcNAc-b4-Man. CMD patients who have mutations in these genes produce a-DG with pathological defects in ECM binding (8, 9) . We next used a solid-phase laminin-binding assay to test whether the GalNAc-b3-GlcNAc-bterminus contributes directly to the binding of a-DG to ECM ligands. Whereas the GalNAc-b3-GlcNAc-b4-Man-modified peptide exhibited significant affinity for Wisteria floribunda lectin (WFA, which recognizes terminal GalNAc residues), this was not the case for laminin-111 (Fig. 2B) . Next we asked whether a defect in synthesis of the GalNAc-b3-GlcNAc-b-terminus prevented O-mannose from being further modified by phosphorylation. We expressed Fc-tagged recombinant DG (DGFc340), which contains the region in which the functional modification occurs (13), in [ 32 P]-orthophosphate-labeled control fibroblasts and CMD patient fibroblasts with mutations in GTDC2 or B3GALNT2 (Fig. 2C) . Indeed, the cells from the CMD patients did not produce [ 32 P]-phosphorylated DGFc340, indicating that phosphorylation of the a-DG O-mannose is inhibited by lack of the GalNAc-b3-GlcNAc-bterminus from the mannose.
To understand how the O-glycan on a-DG is phosphorylated, we synthesized fluorescently labeled GalNAc-b3-GlcNAc-b4-Man by using GTDC2dTM, B3GALNT2dTM, and the acceptor Man-a-MU. We first tested adenosine triphosphate (ATP) as a phosphate donor, by performing the assay on total membrane fractions obtained from rabbit brain with GalNAc-b3-GlcNAc-b4-Man-a-MU Fig. 3. SGK196 phosphorylates GalNAc-b3-GlcNAc-b4-Man. (A) Cell lysates from control fibroblasts and fibroblasts derived from patients with a mutation in SGK196, GTDC2, or B3GALNT2, as well as SGK196 patient-derived fibroblasts ectopically expressing SGK196-Myc-DDK, were subjected to a kinase assay using GalNAc-b 3-GlcNAc-b4-Man-a-MU. Data obtained from three individual experiments are shown, with error bars indicating SD. (B) Reactants from a phosphorylation assay in which SGK196-Myc-DDK was used were separated on a C18 reverse-phase column. GalNAc-b3-GlcNAc-b4-Man-a-MU (left), GlcNAc-b4-Man-a-MU (middle), or Man-a-MU (right) was used as acceptor in the absence (top) or presence (bottom) of ATP. H correlation spectroscopy spectrum of the product depicted in Fig. 3B when GalNAc-b3-GlcNAc-b4-Man-a-MU was used as the acceptor. Assigned cross-peaks were labeled as described in Fig. 1 as the acceptor. Separation of the reactant on a C18 column revealed that GalNAc-b3-GlcNAcb4-Man-a-MU (Fig. 2D) was phosphorylated in the presence of ATP. We further separated the ER and Golgi complex in mouse liver membrane fractions and found that the phophorylation activity resided in the ER fractions ( fig. S7 ). Causative proteins of DG-related disorders whose functions remain unknown include fukutin (FKTN), fukutin-related protein (FKRP), TMEM5, ISPD, and SGK196. Among these, only SGK196 shares homology with known protein kinases, although it is believed to be inactive because of the high divergence of its putative kinase domains from the consensus sequence (14) . We tested its phosphorylation activity in lysates from control fibroblasts and CMD patient fibroblasts with mutations in SGK196, GTDC2, or B3GALNT2. The activity toward GalNAc-b3-GlcNAc-b4-Man-a-MU was lacking only in the SGK196-mutated cells, and this loss was rescued by ectopic expression of c-Myc-DDK (FLAG)-tagged SGK196 (SGK196-Myc-DDK) (Fig. 3A) . When SGK196-Myc-DDK produced in HEK293 cells was incubated with ATP and/or Man-a-MU derivatives, SGK196 exhibited significant phosphorylation activity toward GalNAc-b3-GlcNAc-b4-Man-a-MU. Moreover, this activity was not observed when GlcNAcb4-Man-a-MU or Man-a-MU was used as the acceptor (Fig. 3B) . Phosphorylated GalNAc-b3-GlcNAc-b4-Man-a-MU was not detected when SGK196-Myc-DDK carrying a mutation (Leu C resonances of the product were assigned on the basis of HMQC, HMBC, and H2BC spectra ( fig. S11 and table S2) , and the anomeric configurations were determined by ROE (fig. S12) . The BH1/AC4 and CH1/BC3 cross-peaks detected in the HMBC spectrum confirmed that the GalNAc and GlcNAc residues were attached to GlcNAc and Man via b1-3 and b1-4 linkages, respectively ( fig. S11 ). The phosphate group added by SGK196 was attached to the 6-position of the mannose residue (Fig. 4, A and B) .
We have shown that GTDC2 has a protein O-mannose b1,4-N-acetylglucosaminyltransferase activity, which leads us to designate it as POMGNT2, and that GTDC2 and B3GALNT2 can synthesize a GalNAc-b3-GlcNAc-b-terminus at the 4-position of protein O-mannose. SGK196 phosphorylated the 6-position of O-mannose by using ATP, and on this basis we propose to designate it as a protein O-mannose kinase (POMK). Because SGK196 lacks certain residues required for catalysis by kinases (14) , the mechanism used to catalyze the phosphotransfer reaction is unclear. SGK196 exhibited the phosphorylation activity only when the GalNAc-b3-GlcNAc-b-terminus was linked to the 4-position of O-mannose, indicating that this disaccharide serves as the substrate recognition motif of SGK196. This strict specificity of SGK196 may explain why mutations in GTDC2 and B3GALNT2 cause DG-related disorders although their product does not directly recognize the ECM ligand. Because multiple types of O-mannosyl glycans exist, we propose to designate the O-mannosyl glycan structures as cores M1 to M3 (Fig. 4C) . Although the sialylated core M1 of DG was originally proposed to be responsible for binding to ligands in the ECM (15), recent glycomics analysis suggests that proteins besides DG are subject to modification of sialylated cores M1 and M2 (16) . The fact that LARGE alone could not modify phosphorylated GalNAc-b3-GlcNAc-b4-Man-a-MU by using UDP-Xyl and UDP-GlcA as substrate ( fig. S13 ) suggests that CMD causative proteins (FKRP, FKTN, TMEM5, and B3GNT1) besides LARGE are likely to contribute to maturation of the ECM-binding moiety on the phosphorylated core M3 glycan.
